HNL News

August 08, 2022

Familial Hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
July 06, 2022

A Roadmap to Targeted Therapy in Oncology

Dr. Hina Sheikh, Co-Chief, Section of Dermatopathology at HNL Lab Medicine, contributed on this case report, along with colleagues in medical, surgical and radiation oncology at LV Health Network.
Read More
June 29, 2022

Automation in the Clinical Laboratory

Clinical laboratory automation is essential to deliver high quality results in the most cost effective and efficient way.  Automation requires minimal operator intervention and helps to increase productivity, tracking of specimens within the laboratory, decreased turnaround times, improvements in specimen handling, improved laboratory safety, and minimizes errors.
Read More
June 17, 2022

LYME Disease

As you continue to spend more time outside enjoying the weather, you’ll be sharing your space with some critters you’ll want to be aware of. Deer ticks can carry the bacteria that causes Lyme disease, which can have a critical impact on your health if untreated.
Read More
June 15, 2022

Men's Health Month

In 1994, Congress designated the month of June as Men's Health Month to heighten the awareness of preventable health problems and encourage early detection and treatment of disease among men and boys.
Read More
HNL News

July 06, 2022
Dr. Hina Sheikh, Co-Chief, Section of Dermatopathology at HNL Lab Medicine, contributed on this case report, along with colleagues in medical, surgical and radiation oncology at LV Health Network. It was recently published in Melanoma Research Journal 2022 (article). It gives a personalized treatment roadmap on a patient with inoperable stage III melanoma, who failed multiple standard treatments but subsequently showed response to an investigational therapeutic ulixertinib. Case underscores the value of flexibility in oncologic treatment when patients have failed first line therapies or develop serious side effects. Role of pathology in tumor mutational profiling (to guide targeted therapy) and in assessment of treatment response is highlighted. As ulixertinib is formally being reviewed in multiple clinical trials for several tumor types, authors wanted to bring to attention this case (first to their knowledge) of a patient with advanced melanoma harboring the BRAF D594G mutation that was treated successfully with this ERK inhibitor. Such success stories not only give hope to oncology patients, but they also bring the collective medical community closer to our shared goal of personalized 'precision' medicine. HNL and LVHN are fully committed to this goal.